Education
About Us
Working with TipRanks
Follow Us
Prelude Therapeutics, Inc. (PRLD)
:PRLD
PRLD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.63 - $6.80
Previous CloseN/A
Volume107.75K
Average Volume (3M)229.27K
Market Cap
$48.15M
Enterprise Value$21.53M
Total Cash (Recent Filing)$12.47M
Total Debt (Recent Filing)$18.02M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
May 13, 2025EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding55,154,633
10 Day Avg. Volume373,855
30 Day Avg. Volume229,266
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.60
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.08
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$2.50Price Target Upside267.65% Upside
Rating ConsensusHold
Number of Analyst Covering2
---
Prelude Therapeutics News
PremiumCompany Announcements
Prelude Therapeutics Reports 2024 Financial Results
PremiumCompany Announcements
Prelude Therapeutics Reports 2024 Financial Results and Updates
PremiumCompany Announcements
Prelude Therapeutics Appoints Bryant D. Lim as CFO---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsInitial data for PRT3789 monotherapy shows promising results in upper GI tumors with a 100% ORR in early data.
CollaborationsPrelude announced a collaboration with Pfizer Ignite enabling streamlined access to Pfizer’s significant resources, while retaining full ownership of all its programs.
Investment PotentialPrelude shares represent a unique investment opportunity with significant potential upside.
Bears Say
Financial PerformancePrelude reported $3MM in revenues for 3Q24 with higher SG&A expenses than estimated.
Price Target AdjustmentThe price target for Prelude Therapeutics has been lowered to $4 from $7.
Treatment ChallengesTreatment discontinuations due to treatment emergent adverse events occurred in five patients in the monotherapy cohort.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PRLD FAQ
What was Prelude Therapeutics, Inc.’s price range in the past 12 months?
Prelude Therapeutics, Inc. lowest stock price was $0.63 and its highest was $6.80 in the past 12 months.
What is Prelude Therapeutics, Inc.’s market cap?
Prelude Therapeutics, Inc.’s market cap is $48.15M.
When is Prelude Therapeutics, Inc.’s upcoming earnings report date?
Prelude Therapeutics, Inc.’s upcoming earnings report date is May 13, 2025 which is in 36 days.
How were Prelude Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Prelude Therapeutics, Inc. overvalued?
According to Wall Street analysts Prelude Therapeutics, Inc.’s price is currently Undervalued.
Does Prelude Therapeutics, Inc. pay dividends?
Prelude Therapeutics, Inc. does not currently pay dividends.
What is Prelude Therapeutics, Inc.’s EPS estimate?
Prelude Therapeutics, Inc.’s EPS estimate is -0.47.
How many shares outstanding does Prelude Therapeutics, Inc. have?
Prelude Therapeutics, Inc. has 55,154,633 shares outstanding.
What happened to Prelude Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Prelude Therapeutics, Inc.?
Currently, no hedge funds are holding shares in PRLD
---
Prelude Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.50 (267.65% Upside)
$2.50 (267.65% Upside)
Hedge Fund Trend
Decreased
By 3.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $579.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 7.5%
Last 30 Days ▲ 7.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.75%
12-Months-Change
Fundamentals
Return on Equity
-69.01%
Trailing 12-Months
Asset Growth
-36.79%
Trailing 12-Months
Company Description
Prelude Therapeutics, Inc.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
---
PRLD Stock 12 Month Forecast
Average Price Target
$2.50
▲(267.65% Upside)
Technical Analysis
Kura Oncology
―
IGM Biosciences
―
Revolution Medicines
―
Zentalis Pharmaceuticals
―
Foghorn Therapeutics
―
Best Analysts Covering PRLD
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
-14.35%
reiterated a buy rating 5 months ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -14.35% per trade.
---